Sarah Bernsen

Motor phenotypes of amyotrophic lateral sclerosis – a three-determinant anatomical classification based on the region of onset, propagation of motor symptoms, and the degree of upper and lower motor neuron dysfunction

Self-assessment of amyotrophic lateral sclerosis functional rating scale on the patient’s smartphone proves to be non-inferior to clinic data capture

Serum Cardiac Troponin T Levels as a Therapy Response Marker in Tofersen‐Treated <scp>ALS</scp>

Combination of Serum Neurofilament Light Chain and Serum Cardiac Troponin T as Biomarkers Improves Diagnostic Accuracy in Amyotrophic Lateral Sclerosis

Motor phenotypes and neurofilament light chain in genetic amyotrophic lateral sclerosis—results from a multicenter screening program

Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis – assessment of treatment experience in a multicenter study

Serum neurofilament light chain in distinct phenotypes of amyotrophic lateral sclerosis: A longitudinal, multicenter study

Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in <i>SOD1</i>‐related <scp>ALS</scp>—A multicenter observational study over 18 months

<i>SOD1</i> gene screening in ALS – frequency of mutations, patients’ attitudes to genetic information and transition to tofersen treatment in a multi-center program

Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in <scp>SOD1</scp>‐related <scp>ALS</scp>: Treatment experience in clinical practice

Rituximab Treatment and Long-term Outcome of Patients With Autoimmune Encephalitis